GRAPHIC OMITTED][GRAPHIC OMITTED]


INVESTORS CONTACT:
Susan Mesco
Cytogen Corporation
(609) 750-8213


           CYTOGEN APPOINTS KEVIN BRATTON NEW CHIEF FINANCIAL OFFICER

PRINCETON,  N.J., (OCTOBER 26, 2006) -- Cytogen Corporation (NASDAQ: CYTO) today
announced the  appointment of Kevin Bratton as the Company's new chief financial
officer.  A  finance  executive  with  more  than  35  years  of  experience  in
healthcare,  biotechnology  and  technology,  Mr. Bratton was  previously  chief
financial  officer at Metrologic  Instruments,  Inc.  (NASDAQ:  MTLG),  a global
technology  company.  During his tenure at Metrologic,  Mr. Bratton directed the
company's finance operations during a period of significant growth in sales, net
income, cash flow from operations, and working capital.

"With the recent  addition of two marketed  oncology  products,  SOLTAMOX(R) and
CAPHOSOL(R), our business is poised for substantial growth and we are especially
pleased  to have a seasoned  finance  executive  like  Kevin  joining us at this
important  time in our  history,"  said Michael D. Becker,  president  and chief
executive officer.  "His outstanding  experience and shared vision of the growth
Cytogen can achieve will be an  excellent  complement  to our senior  management
team as we work to maximize the value of our growing  revenue  opportunities  in
the years ahead."

Prior to joining Metrologic Instruments,  Mr. Bratton worked at The JPM Company,
where he served as chief financial  officer from 2000 to 2002 and as director of
external  reporting from 1999 to 2000.  Prior to joining JPM, Mr. Bratton worked
for more than 20 years in the healthcare  sector.  He was vice president finance
and treasurer for the biotechnology  company IGI, Inc., and corporate controller
for the specialty medical company Delmed, Inc. Mr. Bratton began his career with
the public accounting firm Touche Ross & Co. (now Deloitte & Touche LLP). He has
a bachelor of science in business and accounting from Northeastern University.

About Cytogen
- -------------

Founded in 1980, Cytogen is a  biopharmaceutical  company dedicated to advancing
the care of  cancer  patients  by  acquiring,  developing,  and  commercializing
innovative   pharmaceutical   products.  The  Company's  specialty  sales  force
currently  markets  QUADRAMET(R),  PROSTASCINT(R),  and  SOLTAMOX(R) to the U.S.
oncology  market.  QUADRAMET is approved  for the  treatment of pain in patients
whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting  monoclonal
antibody-based  agent to image the  extent and spread of  prostate  cancer,  and
SOLTAMOX is the first  liquid  hormonal  therapy  approved  in the U.S.  for the
treatment of breast cancer in adjuvant and





metastatic  settings.  In early  2007,  Cytogen  plans to  introduce  its fourth
marketed product to the U.S. market, CAPHOSOL, a prescription medical device for
the treatment of oral  mucositis and dry mouth.  The Company is also  developing
CYT-500,  a  third-generation  radiolabeled  antibody to treat prostate  cancer.
Cytogen's  product-focused  strategy  focuses on  attaining  sustainable  growth
through clinical, commercial, and strategic initiatives.

This press release  contains  certain  "forward-looking"  statements  within the
meaning of the Private Securities  Litigation Reform Act of 1995 and Section 21E
of the Securities Exchange Act of 1934, as amended.  All statements,  other than
statements of  historical  facts,  included in this press release  regarding our
strategy,  future operations,  financial  position,  future revenues,  projected
costs,  prospects,  plans  and  objectives  of  management  are  forward-looking
statements.  Such  forward-looking  statements  involve  a number  of risks  and
uncertainties  and investors are cautioned not to put any undue  reliance on any
forward-looking  statement.  There are a number of important  factors that could
cause  Cytogen's  results  to differ  materially  from those  indicated  by such
forward-looking  statements.  In particular,  Cytogen's business is subject to a
number of significant risks, which include,  but are not limited to: the risk of
successfully  marketing  SOLTAMOX  and  CAPHOSOL;  the  risk  of  obtaining  the
necessary  regulatory  approvals;  the  risk of  whether  products  result  from
development  activities;  the  risk  of  shifts  in the  regulatory  environment
affecting sales of Cytogen's  products such as third-party  payor  reimbursement
issues;  the risk  associated  with  Cytogen's  dependence  on its  partners for
development of certain projects, as well as other factors expressed from time to
time in Cytogen's  periodic filings with the Securities and Exchange  Commission
(the "SEC"). As a result,  this press release should be read in conjunction with
Cytogen's  periodic  filings  with  the  SEC.  The  forward-looking   statements
contained herein are made only as of the date of this press release, and Cytogen
undertakes no obligation to publicly update such  forward-looking  statements to
reflect subsequent events or circumstances.

                                      ###